Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla., Aug. 13, 2024 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical;" the "Company"), a leader in advanced energy technology and the manufacturer of Renuvion®, today announced that doctors named Renuvion as the #1 trusted body contouring technology in an independent survey by Wakefield Research.** This recognition underscores the effectiveness of Renuvion's no ...

Apyx Medical Corporation (NASDAQ:APYX) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matthew Hill - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Frank Takkinen - Lake Street Capitals George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. At this ti ...

Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.56%. A quarter ago, it was expected that this medical device maker would post a loss of $0.18 per share when it actually produced a loss of $0.22, delivering a surprise of -22.22%.Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock APYX Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-3 ...

EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook CLEARWATER, FL — August 8, 2024 - Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion , today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. ® ...

Renuvion is the only device FDA-cleared for contracting subcutaneous tissue CLEARWATER, Fla., June 26, 2024 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of the "Renewing Lives" campaign, a nationwide, life-changing give-back program that will provide Renuvion treatments to people who can most benefit from this advanced medical t ...

Apyx Medical Corporation (NASDAQ:APYX) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matt Hill - Chief Financial Officer Conference Call Participants Phillip Paul Dantoin - Piper Sandler Frank Takkinen - Lake Street Capitals Matt Hewitt - Craig-Hallum Capital George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the First Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Me ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock APYX Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001- ...

Apyx Medical (APYX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this medical device maker would post a loss of $0.13 per share when it actually produced a loss of $0.19, delivering a surprise of -46.15%.Over the last four quarters, the company ...

EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook CLEARWATER, FL — May 9, 2024 - Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion , today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024 First Quar ...